Targeting the TGFB axis has advanced rapidly in solid malignancies with phase II trials of a small molecule inhibitor of TGFBR1, demonstrating improved overall survival in hepatocellular carcinoma and unresectable pancreatic cancer [128,129]. The gene discussed is TGFBR1; the disease is hepatocellular carcinoma.